Request Trial
biotechnology-drugs
Incomible / Shutterstock.com
20 June 2014AmericasHector E. Chagoya

Biotechnology drugs: threats and opportunities

Looking at the trends in patents and in the new drugs working their way along the pipelines of the innovative pharmaceutical companies, it’s clear that biotechnology drugs are the future for the treatment of diseases around the world. It’s also clear that personalised medicine will become a reality for more and more people as biotechnology develops further and the performance of drugs improves.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026   A unanimous SCOTUS ruling is being hailed as a major win for Hikma, and for delivering some welcome clarity. Experts tell Marisa Woutersen how its implications could affect pharma patent strategy across the sector.
Americas
Fed Circ rejects Nexus’ appeal in generics row with biopharma firm
8 June 2026   Nexus Pharmaceuticals is knocked back by the US Court of Appeals, which upholds a district court finding that it infringed a rival’s patents.
Americas
Hikma triumphs at SCOTUS in landmark skinny-label ruling
4 June 2026   Justices refuse to place generic drug makers “between a rock and a hard place,” in a landmark ruling clarifying induced patent infringement in pharma.


Editor's picks

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

Editor's picks

Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Americas
Penile implant maker’s $17m trade secret award unravels
20 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026

More features

Hikma v Amarin: Six takeaways from the pivotal ruling
Fed Circ rejects Nexus’ appeal in generics row with biopharma firm
Hikma triumphs at SCOTUS in landmark skinny-label ruling
Pfizer strikes $10.5 billion oncology deal with Chinese biotech
Heated LNP litigation puts Moderna and Acuitas in the spotlight
UPC dispute resolution forum opens with ceremony in Slovenia
J&J unit's valuable heart pump saved by 'rare' patent defence
Federal Circuit tosses $59m trade secrets judgment against EOFlow